Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Enochian Biosciences Inc (ENOB)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Mar-31-23 | Dec-31-22 | Sep-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | | | 37.1% | 34.7% | 36.2% | 38.4% | 8.7% |
| Gross profit | | | | 62.9% | 65.3% | 63.8% | 61.6% | 91.3% |
| Research and development | | | | 41.5% | 38.7% | 39.9% | 40.9% | 47.6% |
| General and administrative | | | | 30.1% | 26.4% | 23.7% | 20.4% | 70.5% |
| EBITDA | | | | -88.7% | -78.6% | -77.3% | -68.8% | -129.4% |
| Depreciation | | | | 0.3% | 0.3% | 0.3% | 0.3% | 1.2% |
| EBIT | | | | -89.0% | -78.8% | -77.5% | -69.1% | -130.6% |
| Pre-tax income | | | | -89.8% | -79.6% | -78.4% | -70.2% | -134.5% |
| Income taxes | | | | 0.0% | 0.0% | 0.0% | 0.3% | 1.2% |
| Net income | | | | -89.8% | -79.6% | -78.4% | -69.8% | -133.2% |
|